111 Capital’s ADMA Biologics ADMA Stock Holding History

111 Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,277	Closed	-$278K	–	442
2025 Q2	$278K	Buy	+15,277	New	+$312K	0.05%	380

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

111 Capital's ADMA Position: Q3 2025 in Review

111 Capital sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 15,277 shares — an estimated $278K sold.

111 Capital first reported a position in ADMA in Q2 2025 and held it in 1 quarter. The position peaked at $278K in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

111 Capital reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 15,277 ADMA Biologics shares in Q3 2025, an estimated $278K.
111 Capital first reported a position in ADMA Biologics in Q2 2025 and held it in 1 quarter.
111 Capital's ADMA Biologics position peaked at $278K in Q2 2025.
365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.